JiaxinNiuMD

Summary

• I graduated from China Medical University. After that, I pursued Ph.D. in molecular pharmacology at University of Illinois in Chicago, Illinois. I completed internal medicine internship and residency training at Cook County hospital in Chicago, Illinois and subsequently received fellowship training in hematology and oncology at Baylor College of Medicine in Houston, Texas.
  
  I am triple board-certified in internal medicine, hematology and medical oncology. I joined Banner MD Anderson Cancer Center in 2016 and has been focusing on clinical practice and research in lung, head & neck cancers.
  
  I have over 20 years of experience in both basic and clinical research. My passion has been early drug development. I am the principal investigator or co-principal investigator of many ongoing clinical trials at BMDACC. Most recently, I participated in Regeneron study as a site-PI, which was published in New England Journal of Medicine in 2018. The study drug, now known as Cemiplimab, was approved by FDA to treat advanced cutaneous squamous cell carcinoma.
  
  Selected ongoing Clinical trials (25 total)
  
  1. An Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
  2. A Phase 1 Study of RGX-104 With or Without Nivolumab in Patients with Advanced Solid Malignancies
  3. A Phase 1b Dose-Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
  4. A Phase I/II study of HB-201 as monotherapy or in combination with nivolumab in patients with human Papillomavirus 16 positive (HPV 16+) confirmed cancers
  5. A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects with
  Relapsed/Refractory HPV16+ Cancers
  6. A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T